Preparation and immungenicity of recombinant protein containing intramolecular adjuvant in SARS-CoV-2 RBD domain.
- Author:
Jingwen JIANG
1
;
Yunlong WANG
2
;
Yulin LI
3
;
Jichuang WANG
3
;
Yiqing ZHANG
2
;
Xudong WANG
4
;
Xiaojun WANG
4
;
Heng ZHANG
4
Author Information
- Publication Type:Journal Article
- Keywords: SARS-CoV-2; immunity; intramolecular adjuvant; recombinant protein
- MeSH: Adjuvants, Immunologic; Aluminum; Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19/prevention & control*; COVID-19 Vaccines/genetics*; Humans; Mice; Mice, Inbred BALB C; Recombinant Proteins/genetics*; SARS-CoV-2/genetics*; Spike Glycoprotein, Coronavirus/genetics*; Tetanus Toxin; Tuftsin; Vaccines, Subunit; Viral Vaccines
- From: Chinese Journal of Biotechnology 2022;38(9):3353-3362
- CountryChina
- Language:Chinese
- Abstract: A fusion protein containing a tetanus toxin peptide, a tuftsin peptide and a SARS-CoV-2S protein receptor-binding domain (RBD) was prepared to investigate the effect of intramolecular adjuvant on humoral and cellular immunity of RBD protein. The tetanus toxin peptide, tuftsin peptide and S protein RBD region were connected by a flexible polypeptide, and a recombinant vector was constructed after codon optimization. The recombinant S-TT-tuftsin protein was prepared by prokaryotic expression and purification. BALB/c mice were immunized after mixed with aluminum adjuvant, and the humoral and cellular immune effects were evaluated. The recombinant S-TT-tuftsin protein was expressed as an inclusion body, and was purified by ion exchange chromatography and renaturated by gradient dialysis. The renaturated protein was identified by Dot blotting and reacted with serum of descendants immunized with SARS-CoV-2 subunit vaccine. The results showed that the antibody level reached a plateau after 35 days of immunization, and the serum antibody ELISA titer of mice immunized with recombinant protein containing intramolecular adjuvant was up to 1:66 240, which was significantly higher than that of mice immunized with S-RBD protein (P < 0.05). At the same time, the recombinant protein containing intramolecular adjuvant stimulated mice to produce a stronger lymphocyte proliferation ability. The stimulation index was 4.71±0.15, which was significantly different from that of the S-RBD protein (1.83±0.09) (P < 0.000 1). Intramolecular adjuvant tetanus toxin peptide and tuftsin peptide significantly enhanced the humoral and cellular immune effect of the SARS-CoV-2 S protein RBD domain, which provideda theoretical basis for the development of subunit vaccines for SARS-CoV-2 and other viruses.
